pediatric ALL – Medxy AI

Reassessing Total Body Irradiation in Young Children with ALL: Long-Term Safety and Outcomes

By MedXY 08/25/2026

A French longitudinal study finds no increased long-term complications or compromised quality of life in children under 4 years undergoing TBI-based HSCT for acute lymphoblastic leukemia, challenging prior age restrictions.

Hematology-Oncology news Pediatrics

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring

By MedXY 04/24/2026

A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearranged subtypes.

Hematology-Oncology news Pediatrics

Withholding Two Daunorubicin Doses in Induction Preserves Outcomes and Lowers Fungal Risk in Favorable-Risk Pediatric B-ALL

By MedXY 12/08/2025

In children with favorable B-lineage ALL, omission of two daunorubicin doses late in induction was noninferior for 5-year EFS and OS and associated with fewer invasive fungal infections, supporting reduced anthracycline exposure in selected low-risk patients.